Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday.
Several other equities analysts have also commented on the stock. HC Wainwright restated a “neutral” rating and set a $6.00 price target on shares of Aardvark Therapeutics in a research report on Monday, July 20th. Weiss Ratings upgraded shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd. Morgan Stanley reissued an “underweight” rating and set a $3.00 target price (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. BTIG Research cut shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Finally, B. Riley Financial dropped their price target on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Aardvark Therapeutics currently has an average rating of “Hold” and an average target price of $16.30.
Get Our Latest Stock Report on Aardvark Therapeutics
Aardvark Therapeutics Price Performance
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.21. As a group, research analysts anticipate that Aardvark Therapeutics will post -3.22 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Aardvark Therapeutics during the second quarter valued at about $42,000. China Universal Asset Management Co. Ltd. acquired a new stake in Aardvark Therapeutics in the fourth quarter worth about $47,000. Persistent Asset Partners Ltd bought a new position in Aardvark Therapeutics in the 4th quarter valued at about $56,000. New York State Common Retirement Fund bought a new position in Aardvark Therapeutics in the 2nd quarter valued at about $99,000. Finally, MetLife Investment Management LLC bought a new position in Aardvark Therapeutics in the 4th quarter valued at about $102,000.
About Aardvark Therapeutics
Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.
The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.
Read More
- Five stocks we like better than Aardvark Therapeutics
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
